Why Australian men are turning to their pharmacies for healthcare

The speculation of a proposed pre-negotiation memorandum of understanding between the two manufacturer groups can be interpreted as further evidence of planning.

At the top of the field, GSKlimbers have established themselves as the current frontrunners with over $22,000 already raised.

Early examples appear designed to attract attention. High-profile medications, such as GLP-1 weight-loss therapies, are advertised with steep discounts. 

In 2025, nearly 100,000 cases and more than 300 flu-related deaths were recorded in Queensland. Most hospitalisations and deaths were among unvaccinated people.

Artificial intelligence is no longer a future concept in healthcare. It will be the focus of an upcoming breakfast in Sydney, bringing together pharmaceutical and healthcare executives to examine how AI can be adopted while regulatory frameworks continue to evolve.

Australia's complex federation creates a 'status quo' bias on policy. This is particularly true in health. Major reform is very difficult beyond financing changes that often buy time and delay problems.

At a summit hosted by the Generic and Biosimilar Medicines Association in Canberra yesterday, Australia’s political and policy leaders warned that the nation’s medicines system is approaching a critical inflection point.

In his opening address, Health Minister Mark Butler equated HTA reform with ensuring supply and identified both as core priorities in his agenda, clearly signalling the terms of engagement for an upcoming negotiation.

Australia’s nuclear medicine sector is urging the Commonwealth to establish a dedicated national funding stream for radiopharmaceutical cancer therapies

Pfizer has reported encouraging mid-stage clinical results for an experimental once-monthly injectable obesity treatment, strengthening its push into one of the most competitive and fast-growing areas of global pharmaceuticals.

The industry has every right to highlight the wording of its agreements in pushing for any new negotiation beyond the May Budget, but it is critical that it considers history and some complex realities.

Australians living with rare and less common cancers are facing significantly greater gaps in care and support than those diagnosed with more common cancers, according to new national survey findings released to mark World Cancer Day.

The association has called on the Federal Government to use the 2026–27 Budget to reverse Australia’s growing lag in access to innovative medicines, warning that patients are increasingly missing out on treatments already available overseas.

AusBiotech and Medicines Australia have established a joint Advanced Therapies Advisory Group to help shape the future of cell and gene therapies in Australia.

JAFA is now seeking a new CEO to build on Angela McKay's achievements, lead the organisation into its next phase, and advance its strategic priorities.

Without whole-of-government action, warned AusBiotech Chief Executive Officer Rebekah Cassidy, Australia may continue to lose ground to countries that have already identified life sciences as a cornerstone of economic growth and national resilience.

The appointment comes at a critical time for the national peak body, it said, which represents more than seven million Australians living with arthritis and musculoskeletal conditions.

According to Sandoz Australia and New Zealand General Manager Clint Holland, improving access requires more than adding medicines to the PBS.

Australian company PYC Therapeutics has announced a capital raising of up to $653 million, a scale of funding rarely seen on the Australian Securities Exchange and one that places the Perth-founded biotech among a small group of local life sciences firms able to attract global capital at this magnitude.

The committee emphasised that appropriate use, stakeholder engagement, and a post-listing review after three years would be critical to the sustainability of this new broad-listing model.

The Government has announced an additional $25 billion for public hospitals over five years, representing close to two PBSs, while NDIS spending continues to rise by $1 billion every few months. Can anyone seriously still argue that there is no new money available to invest in medicines?